Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dendreon Corporation (DNDN): What You Should Know

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of Dendreon Corporation (NASDAQ:DNDN) — developer of the Food and Drug Administration-approved immunotherapy treatment Provenge to treat castration-resistant prostate cancer — sank like a stone, losing as much as 17% after reporting disappointing first-quarter results.

Dendreon Corporation (NASDAQ:DNDN)

So what: For the quarter, revenue for Provenge actually fell 18% year-over-year to $67.6 million despite the company’s aggressive advertising campaign, missing the Street’s estimates of $80 million in sales. Net loss clocked in at $0.48 per share, which was right in line with estimates. Dendreon Corporation (NASDAQ:DNDN)’s CEO, John Johnson, blamed the revenue shortfall on his company’s difficulty in gaining insurance approval for the pricey treatment, and increased competition, which included Medivation Inc (NASDAQ:MDVN)‘s Xtandi getting a recommendation for approval to treat advanced prostate cancer from the Committee for Medicinal Products for Human Use in Europe last month. Dendreon Corporation (NASDAQ:DNDN)’s remaining cash balance fell to $337.3 million.

Now what: Dendreon Corporation (NASDAQ:DNDN) really needs to attack this from two fronts at once. Without question, if Dendreon Corporation (NASDAQ:DNDN) has any hope of righting this ship, it’ll need to get Provenge approved in Europe. Approval there would likely double sales within the first two years. Second, it needs to slow the bleeding in the U.S. The company’s restructuring should demonstrate noticeable expense savings in the second half of this year, but it’s going to need to work with insurers to comfort physicians who are afraid of not being reimbursed after prescribing Provenge. It was an ugly quarter indeed, but I haven’t given up on Dendreon Corporation (NASDAQ:DNDN) just yet.

The article Why Dendreon Had Its Battleship Sunk originally appeared on Fool.com is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of Dendreon.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Loading Comments...